Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05868577 · ClinicalTrials.gov registry record · Phase 1

Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis

A Phase 1 study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target

NCT05868577: Completed Phase 1 study, sponsored by Wake Forest University Health Sciences.

NCT05868577 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05868577, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target

Study Summary

Although no single treatment has shown superiority, short-term pain relief may be offered via a targeted local corticosteroid injection (CSI), used often in combination with local anesthetic (LA), which may reduce plantar fasciitis symptoms for up to 1 month. Moreover, administering a CSI is relatively quick and easy for any Provider to perform, though it is not without potential deleterious side effects and risks, including fibroblast degradation, fat pad atrophy, skin depigmentation, and even plantar fascia rupture.

Primary Outcome

A sheet of paper with a printed VAS scale will be given to the patient. The patient will be instructed to make a bold dot on the line based on how they rate their general heel pain, using the parameters listed on the scale (0 meaning no pain, 20 meaning mild pain, 50 meaning moderate pain, 80 meaning extreme pain, and 100 meaning the worst pain imaginable). Range 0-100.

Interventions

  • DRUG Corticosteroid injection (CSI) with local anesthetic (LA)
  • DRUG Local anesthetic (LA) with Saline injection

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2023-10-18
Est. Completion 2024-09-18
Phase Phase 1
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT05868577 record still lists

NCT05868577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).

The record links to 0 conditions, and to 2 interventions - of which Corticosteroid injection (CSI) with local anesthetic (LA) is the first listed.

NCT05868577 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05868577 about?

NCT05868577 is a clinical study titled "Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis". Although no single treatment has shown superiority, short-term pain relief may be offered via a targeted local corticosteroid injection (CSI), used often in combination with local anesthetic (LA), which may reduce plantar fasciitis symptoms for up to 1 month. Moreover, administering a CSI is relativ...

What is the current status of trial NCT05868577?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-10-18. Estimated completion is 2024-09-18.

What interventions are being tested in trial NCT05868577?

The interventions under investigation include: Corticosteroid injection (CSI) with local anesthetic (LA) (DRUG), Local anesthetic (LA) with Saline injection (DRUG).

Who is sponsoring clinical trial NCT05868577?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05868577's enrollment target sits among peer trials

41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05868577, the US trial registry maintained by the National Library of Medicine. NCT05868577 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.